Affordable Access

Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group.

Authors
Type
Published Article
Journal
Clinical and Diagnostic Laboratory Immunology
Publisher
American Society for Microbiology
Volume
3
Issue
6
Pages
769–773
Source
UCSC Bioinformatics biomedical-ucsc
License
Unknown

Abstract

Salivary binding antibodies induced by candidate human immunodeficiency virus type 1 (HIV-1) vaccines in healthy, HIV-1 uninfected volunteers were assessed in a clinical trial evaluating intramuscularly injected HIV-1MN recombinant gp120 (rgp120) vaccine alone or with HIV-1IIIB rgp120 vaccine. The two rgp120 vaccines induced envelope glycoprotein-specific immunoglobulin G (IgG) and IgA antibodies in whole saliva and serum.

Report this publication

Statistics

Seen <100 times